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Neurological diseaseTransgenic mouse models have vastly contributed to our knowledge of the genetic and molecular pathways
underlying the pathogenesis of neurological disorders that affect millions of people worldwide. Not only
have they allowed the generation of disease models mimicking the human pathological state but they have
also permitted the exploration of the pathological role of speciﬁc genes through the generation of knock-out
and knock-in models. Classical constitutive transgenic mice have several limitations however, due to
behavioral adaptation process occurring and conditional mouse models are time-consuming and often lack
extensive spatial or temporal control of gene manipulation. These limitations could be overcome by means of
innovative methods that are now available such as RNAi, viral vectors and large cloning DNA vectors. These
tools have been extensively used for the generation of mouse models and are characterized by the superior
control of transgene expression that has been proven invaluable in the assessment of novel treatments for
neurological diseases and to further investigate the molecular processes underlying the etiopathology of
neurological disorders. Furthermore, in association with classical transgenic mouse models, they have
allowed the validation of innovative therapeutic strategies for the treatment of human neurological
disorders. This review describes how these tools have overcome the limitations of classical transgenic mouse
models and how they have been of value for the study of human neurological diseases.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Neurological disorders are a family of more than 600 different
diseases that affect millions of people worldwide. Due to the
extension of life expectancy and aging of population, the occurrence
of these diseases in the future is likely to increase. Our knowledge of
the molecular pathways underlying the pathogenesis of this wide
class of disorders has been remarkably improved through the use of
transgenic mouse models [1]. These animal models have played an
important role in the study of neurological diseases thanks to the
possibility to stably introduce normal or modiﬁed genes into, or
indeed, eliminate genes from a living organism. They have allowed
the generation of disease models that resemble the human patholog-
ical state and provided convincing tools to test and validate new
possible therapeutic approaches [2]. They have also lead to the
exploration of the pathological signiﬁcance of a putative target gene in
neurological disorders. Recently, thanks to the advent of several
functional genomic technologies such as microarray-based analysis or
proteomic platforms a wide number of putative genes, potentiallyroscience CEDD, GlaxoSmithK-
Verona, Italy. Tel.: +39 045
ll rights reserved.involved in a speciﬁc disorder have been identiﬁed. However the
effective patho-physiological signiﬁcance of these genes requires in
vivo validation. One of the methods most broadly used for in vivo
target validation is the genetic manipulation of the gene of interest
and the analysis of the resulting behavioral phenotype and/or of the
physiological alterations. Traditionally transgenic animal models
were created through homologous recombination in embryonic
stem (ES) cells such that the gene of interest was either stably
knocked out or over-expressed in mice. However the traditional
transgenic mouse models carrying constitutive mutations were often
associated with several disadvantages such as genetic compensation
and developmental adaptations that couldmask a clear phenotype [3].
Therefore in the last decades an extensive research has been carried
out to develop technical strategies that allow the introduction or
suppression of a target protein in a spatial and temporal manner. In
this context tissue-speciﬁc transgenic expression or the use of
inducible systems to temporally control transgene expression have
been successfully applied to generate mice models beneﬁcial for
deepening our knowledge of the etiology of neurological disorders [4].
Nowadays several innovative methods for gene manipulation such as
RNA interference (RNAi), viral vectors and DNA vectors as yeast-
derived artiﬁcial chromosomes (YACs) or bacterial-derived artiﬁcial
chromosomes (BACs) have become available and have been success-
fully employed to create more sophisticated animal models which
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[5–7]. These modern technologies offer the main advantage of
allowing rapid and speciﬁc genetic manipulation in several species
compared with the classical transgenic methodology. This review
describes the application of these innovative methods in developing
mouse models for neurological disorders and how they have
overcome some of the restrictions of embryonic genetic manipulation.2. RNA interference
RNAi is an evolutionary conserved natural process of post-
transcriptional gene silencing, ﬁrst demonstrated by Fire and
colleagues [8] in 1998 in the worm Caenorhabditis elegans. RNA
interference is deﬁned as the process by which double-stranded (ds)
RNA molecule silences gene expression, either by inducing the
degradation or destabilization of complementary mRNA or by
inhibiting translation. Although it is only a recent discovery, RNAi
has soon become an important tool in drug discovery and had opened
several biological applications and new therapeutic strategies.
Elbashir and colleagues [9] in their studies of RNAi processes in Dro-
sophila melanogaster embryo extracts showed that long dsRNA
substrates could be cleaved into short interfering dsRNA species
(siRNAs) of ∼22 nucleotides (nt), able to anneal to the target mRNA
driving its degradation. They also showed that the introduction of a
chemically synthesized siRNA of 21–22 nt to these extracts facilitated
the degradation of the homologous target mammalian genes, thereby
evading the interferon response. Another technical advance came
from the demonstration that siRNAs could be endogenously
expressed in the form of short hairpin RNAs (shRNAs) by a DNA
vector transfected into a cell. The vector contains a shRNA cassette
with a promoter that drives the transcription of a fold-back stem–loop
RNA structure. This shRNA is then processed to siRNA by the RNAi
machinery and is therefore able to induce target-gene silencing in
mammalian cells. In addition to its power as a tool for gene silencing
in biology, RNAi is also a conserved endogenous system of gene
expression regulation throughmicro RNAs (miRNAs) [10,11]. miRNAs
have been cloned from various organisms and cells (the ﬁrst identiﬁed
was lin-4 from C. elegans) and in vertebrates miRNAs are currently
estimated to comprise 1% of animal genes [12]. Through experiments
of over-expression or knockdown of individual miRNA, it has been
demonstrated that miRNAs affect the mRNA levels of many genes and
regulate several cellular processes, such as the control of cellular state
and the developmental process [13]. Recent evidences suggest that a
large number of miRNAs are expressed in the mammalian brain in a
spatio-temporal manner, suggesting a crucial role of these molecules
in regulating brain development and neuronal cell fate [11,14]. In fact,
conditional transgenic mice lacking the activity of Dicer, the enzyme
necessary for the miRNA synthesis, die postnatal due to neural
hypotrophy [15]. Evidence suggests that each miRNA potentiallyFig. 1. Tools available for genetic manipulation in the mouse nervous scontrols the expression of hundreds of mRNAs in the brain, suggesting
the presence of feedback control loops or indicating moderate
modiﬁcation at the level of target proteins expression. Not surpris-
ingly several miRNAs have been shown to be associated with different
neurological and psychiatric disorders since even subtle modiﬁcations
of neuronal physiology of the human central nervous system (CNS)
may be associated with strong effects on cognitive or neurological
functions [16,17].2.1. RNAi machinery
The miRNAs have been shown to share much of the same
machinery of siRNA-induced gene silencing that is characterized by
evolutionary conserved enzymes. The siRNAs, characterized by 2 nt 3′
overhangs and 5′-phosphate and 3′-hydroxyl groups, are incorporat-
ed in the multi-protein complex known as the RNA-induced silencing
complex (RISC) that unwinds the duplex siRNA into single stranded
siRNA, using an ATP-dependent RNA-helicase activity. The antisense
strand of the duplex guides the RISC complex to the homologous
mRNA, targeting it for degradation (Fig. 2a). As previously seen, the
siRNAs can also be generated in the cytosol by the evolutionary-
conserved Dicer enzyme, starting from longer dsRNAmolecules in the
form of a hairpin structure. These shRNAs can be produced from a
DNA template under the control of RNA polymerase (pol) II or III
promoters (Fig. 2b). The siRNA produced from the shRNA construct is
then recognized by the endogenous RNAi machinery and is therefore
able to induce target-gene silencing in mammalian cells. The miRNAs
are endogenous short single-stranded RNAs of roughly 22 nt
produced by cleavage of longer (∼70 nt) endogenous precursors
with imperfect hairpin RNA structure (pre-miRNA) by the Dicer
enzyme (Fig. 2c), which suppress the expression of partially
complementary target mRNAs by translation inhibition or mRNA
destabilization rather than mRNA degradation [10].2.2. RNAi application for neurological disorders
Neurological disorders are often associated with mutations at the
level of speciﬁc genes. In some cases the mutant genes are associated
with an abnormal gain of function that leads to the pathological state.
In this context, the advent of interfering processes naturally silencing
the expression of speciﬁc gene could help in understanding the
pathological process or investigating the therapeutic potential of the
target gene. Moreover, conditional genetic manipulation techniques
that allows the creation of mouse models with a spatial and temporal
control over gene expression often lack sufﬁcient spatial control and
are time consuming. In this context, RNAi can be used to generate
localized gene knockdown inmouse brain for rapid production of new
genetic disease models of interest for neurological disorders.ystem and their applications in the ﬁeld of neurological disorders.
Fig. 2. The RNA interference pathway. (a) Short interfering RNA: the siRNA is characterized by 5′ phosphorylated ends, a 19-nt duplexed region and 2 nt unpaired and
unphosphorylated 3′ ends. This double stranded RNA molecule is recognized by the multiprotein complex RISC, which unwinds the siRNA duplex and incorporates the single
stranded antisense strand. The antisense strand guides RISC to the target mRNA, driving its endonucleolytic cleavage. (b) Short hairpin RNA: the siRNA is produced by the Dicer-
mediated cleavage of longer dsRNA precursor molecules as those in the form of a hairpin structure. In the shRNA molecule the sense and antisense strands are separated by a loop
sequence. This shRNA can be produced by the transcription of the shRNA construct mediated by Pol II or Pol III promoters. (c) The microRNA pathway. Dicer can also cleavage the
≈70 nt hairpin miRNA precursor to produce the≈22 nt miRNA which is then incorporated in the miRNA-protein complex (miRNP). Unlike siRNAs, the miRNAs pair with partial
sequence complementarity to the target mRNA and lead to translational repression or decrease mRNA stability.
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other silencing technologies such as the conventional antisense or the
ribozyme methods such as higher speciﬁcity, versatility (interfering
RNA can be designed virtually against any gene), and efﬁciency (in
many cases, genes can be silenced by over 90%). Moreover since it
does not induce the complete silencing of the target gene, it allows it
to mimic the pharmacological manipulation of the gene itself [18].
However the generation of neurological models using RNAi faces a
major problem of in vivo brain delivery since the blood–brain-barrier
limits the passive entry of materials from the peripheral circulation.
Themethodologies for RNAi application inmouse brain are essentially
two: direct pre-synthesized or chemically modiﬁed siRNAs delivery
using several carriage systems or prolonged vector-mediated siRNA
production. The simplest way to deliver siRNAs is to locally inject
them in the desired region of the brain. Successful gene knockdown in
mouse brainstem and hypothalamic nuclei has been reported with
this method, but only a transient and highly restricted suppression
around the injection site was achieved [19]. Transfection reagents
such as nanoparticles, liposomes or other cationic carriers able to
efﬁciently deliver siRNA in the mouse brain have been recently
described [20,21]. As example, Peters and colleagues [22] employed
polyethyleneimine (PEI) to deliver siRNAs targeting cyclic AMP-
responsive element-binding protein (CREB) and protein phosphatase
1 (PP1) into the dorsal hippocampus of mice, in order to investigate
the role of these genes in mediating contextual memory formation.
However these methods have been reported to be associated with
neurotoxic effects [23]. Alternatively, electroporation can be used for
siRNA-delivery and subsequent gene silencing [24], but very few
reports in the literature describe the real efﬁcacy of these approaches
to study neurological disorders. Recently, Thakker and colleagues
have successfully applied the osmotic mini pump technology to
efﬁciently deliver siRNAs and mediate gene silencing throughout the
whole mouse brain and without neurotoxic effects [25-27]. The siRNA
released from the pump by the osmotic pressure is directed via a
catheter to a stereotaxically placed cannula for infusion into the brain,
resulting in prolonged siRNA administration and diffusion throughout
the whole brain. The dopamine transporter (DAT) protein was
reduced in the substantia nigra compacta and ventral tegmental
area after infusion of an unmodiﬁed siRNA into the dorsal thirdventricle of mice over a 2-week period. DAT suppression was
associated with a time-dependent hyperlocomotor phenotype, sim-
ilar to that obtained after infusing a pharmacologically-selective DAT
inhibitor. DAT is the key modulator of dopamine release into the
synapse and is therefore implicated in the control of dopamine action
on locomotion, emotion, reward and cognition. Similarly, suppression
of the serotonin transporter (SERT) gene, implicated in the etiology of
anxiety and depression, was achieved after a 2-week siRNA infusion
into the dorsal third ventricle. This decrease was reﬂected in an
antidepressant-like behaviour in themouse forced swim test, an effect
identical to that obtained from mice receiving a pharmacologically-
selective SERT inhibitor. Indeed, the application of RNAi to suppress
SERT in adult mouse brain represents a major advantage over the
classical SERT knock-out mouse model since these knock-out mice
display a paradoxical depression-related behavior probably due to
developmental adaptations deriving from early life absence of SERT
[28]. Therefore RNAi-induced knockdown provides a superior model
for investigating the role of SERT in the adult brain in an easier and
less difﬁcult time-consuming manner compared to the generation of
conditional knock-out animals. Similarly, osmotic mini pumps were
used for siRNA-induced knockdown of the metabotropic glutamate
receptor 7 (mGluR7) to investigate the role of this receptor in the
extinction of aversive memories in two different amygdala-depen-
dent tasks [27]. Overall these data showed the efﬁcacy of osmotic mini
pump in delivering siRNAs in the mouse brain to produce speciﬁc and
bilateral knockdown of gene expression and this is particularly useful
when the pattern of expression of the target gene is widespread in the
brain or is not completely understood [29]. However a big
disadvantage of this method is that it requires a large amount of
chemically modiﬁed siRNA in order to produce sustained silencing
due to the relative instability of RNA molecules.
Direct delivery of siRNAs to the peripheral nervous system (PNS) is
less demanding compared to the brain since the PNS is more
amenable to deliver than to the CNS and has been successfully
employed in the study of neuropathic and visceral pain. For example,
siRNA targeting the vanilloid receptor 1 (TRPV1) was directly injected
intrathechally into a mouse model of visceral pain producing a
signiﬁcant analgesic effect similar to the reduction of pain sensitivity
observed after administration of an analgesic compound [30].
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One of the major disadvantages of using pre-synthesized siRNA in
vivo is the transient nature of gene knockdown since small RNA
molecules are relatively unstable in the extracellular and intracellular
environment due to the presence of RNA degrading enzymes
(RNAses). Double-stranded RNA is more stable than single strand
RNA and even though chemical modiﬁcations increasing the stability
of siRNA have been reported, these have, so far, not allow prolonged
gene silencing in vivo. Consequently, DNA vectors with RNA pol III
promoters such as the RNase P H1 or the U6 small nuclear promoter
have been developed to constitutively express shRNAs in order to
achieve a long-lasting siRNA production intracellularly. RNA pol III
promoters efﬁciently direct the synthesis of small non-coding RNA
with well-deﬁned ends but transfer RNA (tRNA) promoters and RNA
pol II-based cytomegalovirus (CMV) promoters have been also
successfully used [31]. Recently, several groups employed miRNA-
based expression cassettes to express artiﬁcial miRNAs resembling
the stem–loop structure of endogenous precursor miRNA allowing
these artiﬁcial miRNAs to enter the miRNA pathway and to be
processed into very high level of mature miRNAs. These artiﬁcial
miRNAs have been shown to effectively silence target gene expression
and miRNA-expressing vectors have been developed based on an
artiﬁcial miRNA scaffold derived from human miR genes and are now
commercially available [32]. Few cases of the delivery of shRNA- or
miRNA-plasmids using transfection agents or electroporation have
been reported as these have lead to neurotoxic effects. For example,
Makimura and colleagues [19] reported the transient silencing of
agouti-related protein (AGRP) in the hypothalamic arcuate nucleus of
adult mice with liposomal transfection of an H1 promoter-driven
shRNA expression vector. Osmotic mini pumps have been employed
to deliver siRNA-expressing plasmids to neural neoplastic cells in
order to investigate the effect of silencing potential oncogenic
proteins in brain tumor growth and invasion. Lakka and colleagues
[33] employed osmotic mini pump to deliver a CMV-promoter
plasmid expressing siRNAs against urokinase-type plasminogen
activator receptor (uPAR) and matrix metalloproteinase-9 (MMP-9)
in glioblastoma-bearing nude mice. siRNA expression resulted in a
total regression of the pre-established intracerebral tumor growth,
demonstrating that RNAi could be an effective tool to target genes
involved in tumor cell invasion. Recently, encapsulated and coated
siRNA-expression vectors, able to cross the blood-brain-barrier, haveTable 1
Advantages and disadvantages of the different viral vectors most used for gene transfer in
Viral vector Advantages
Retroviral vectors Large insert capacity for transgene (b7–8 kb).
Broad cell tropism.
Stable and high transgene expression.
Relatively easy generation of high recombinant virus titers.
Lentiviral vectors Large insert capacity for transgene (10 kb).
Broad cell tropism.
Infect dividing and non-dividing cells.
Stable and high transgene expression.
Adenoviral vectors Large insert capacity for transgene (7–8 kb).
Broad cell tropism.
Infect dividing and non-dividing cells.
High transgene expression.
Relatively easy generation of high recombinant virus titers.
Adeno-associated
viral vectors
Broad cell tropism.
Infect dividing and non-dividing cells.
Prolonged and high transgene expression.
Low immunogenicity and nonpathogenic.
Herpes simplex
viral vectors
Large insert capacity for transgene (up to 50 kb).
Broad cell tropism.
Infect dividing and non-dividing cells.
Generation of high recombinant virus titers.
Natural tropism to neuronal cells.been developed as a potential new gene therapy for silencing
oncogenic genes in brain cancer [34]. These vector-encapsulating
liposomes (PILs) are externally conjugated to polyethylene glycol
(PEG) to extend their half-life in the bloodstream and bind receptor-
speciﬁc peptidomimetic monoclonal antibodies that facilitate brain-
speciﬁc delivery. Encapsulated plasmids expressing siRNA targeting
the epidermal growth factor receptor (EGFR) were injected intrave-
nously in adult severe combined immunodeﬁcient mice implanted
with human U87 gliomas. The targeted gene was successfully silenced
and the survival time of shRNA-expressing mice approximately
doubled, suggesting the efﬁcacy of this strategy for experimental as
well as therapeutic knockdown of oncogenes in the brain tumours
[35].
Undoubtedly the most investigated method to deliver and express
siRNA or miRNA in the brain is by means of recombinant viral vectors.
Viruses are naturally evolved gene vehicles that can be engineered for
the delivery of the desired sequences into host cells. The several
viruses available ensure broad tropism and efﬁcient transduction of
different mammalian cells (Table 1). In the main, the viral vectors that
have been employed to mediate prolonged RNAi in the brain are
derived from lentivirus (LV), adenovirus (Ad), adeno-associated-virus
(AAV) and herpes simplex virus (HSV). Given their inability to
transduce non-dividing or post-mitotic cells, the use of oncoretro-
viruses for targeting neuronal gene expression in vivo is limited. On
the contrary, recombinant LV vectors based on both human
immunodeﬁciency virus (HIV-1) and equine infectious anaemia
virus (EIAV) have been successfully employed to obtain long-term
expression of siRNAs and subsequent gene silencing in the brain [36].
In the ﬁrst proof-of-concept study, an HIV-1-derived lentiviral vector
expressing an shRNA targeting the enhanced green ﬂuorescent
protein (eGFP) under the control of a U6 promoter was injected
into the striatum of adult mice [37]. One week after injection, eGFP
expression from a co-injected eGFP-encoding lentiviral vector was
completely silenced. Recently, lentiviral-mediated RNAi in mice was
employed to investigate the potential of a new therapeutic approach
for refractory epilepsy through focal cell-mediated release of
adenosine to effectively suppress seizures by local augmentation of
the adenosine system. Lentiviral constructs were used for the
expression of anti-adenosine kinase (ADK) targeting miRNAs to
mediate downregulation of ADK, the major adenosine-removing
enzyme, in human mesenchymal stem cells (hMSCs), which would
be compatible with autologous cell grafting in patients [38]. Adultthe nervous system.
Disadvantages
No infection of non dividing cells.
Possible insertional mutagenesis for random integration into host genome.
Vector instability.
Possible insertional mutagenesis for random integration into host genome.
Immune response to viral proteins.
Transient transgene expression.
Limited capacity for transgene (4 kb).
Difﬁcult generation of high virus titers. Requirement of helper virus for replication.
Possible toxicities.
Risk of recombination.
Transient transgene expression (prolonged in neurons).
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susceptible to seizures, demonstrating the efﬁcacy of this approach for
the generation of patient identical autologous adult stem cell grafts for
the treatment of epilepsy. Similarly, lentiviral-mediated RNAi was
employed to silence a neuronal cell adhesion molecule, L1CAM, in
glioma cells before injection into immunocompromised mice or
directly in the established tumor. The L1CAM-siRNA expression
resulted in suppression of tumor growth and an increase in the
survival of tumor-bearing animals thus conﬁrming the potential of
both viral and non-viral RNAi gene therapy for the treatment of human
brain cancer [39]. Adenoviruses and adeno-associated viruses are
single and double-stranded DNA viruses, respectively, which exhibit
comparable transduction efﬁciencies in neuronal cells to lentiviruses.
Local injections of recombinant adenoviral shRNA constructs have
been shown to induce substantial knockdown of eGFP expression in
the striatum of adult eGFP-expressing mice [40]. AAV-based vectors
have been also extensively used to mediate neuronal RNAi in mice for
the study of neurological disorders. Hommel and colleagues [41]
investigated the effect of tyrosine hydroxylase (TH) silencing in the
substantia nigra compacta and ventral tegmental area of adult mice.
TH is a key enzyme for the production of dopamine and the
degeneration of dopaminergic neurons in the midbrain substantia
nigra compacta is the primary cause of Parkinson disease. Hommel et
al. developed AAV-shRNA vectors targeting TH mRNA and reported
shRNA-mediated downregulation of TH that persisted for a period of
up to 50 days post-transduction and rostrocaudally spread across the
substantia nigra compacta. This localized gene knockdown was
coupled to a modiﬁed behaviour, in speciﬁc a motor-deﬁcit and a
reduced response to psychostimulant.
2.4. Viral-vector mediated RNAi for neurodegenerative disorders
Despite the useful application of RNAi in investigating the
functional role of target genes in a speciﬁc behaviour or a
physiological process, a major application of viral vector-mediated
RNAi in the brain has been the exploration of the potential
therapeutic efﬁcacy of RNA interference for neurodegenerative
disorders. Thanks to the high speciﬁcity of RNAi-mediated gene
silencing, RNA interference has shown therapeutic efﬁcacy in several
mouse models of human neurological conditions [42]. Moreover, in
combination with the long-lasting expression of siRNAs achieved by
viral vectors, it represents a promising therapeutic option for
treating neurodegenerative diseases [43]. Several groups have
employed RNAi to target dominantly inherited genes associated
with neurodegenerative disorders such as spinocerebellar ataxia
(SCA), Huntington's disease (HD) and Amyotrophic Lateral Sclerosis
(ALS). Dominant mutations in the human Cu/Zn superoxide
dismutase (SOD1) gene, one of the causes of familial ALS, lead to
progressive death of motoneurons through a gain-of-function
mechanism. The efﬁcacy of RNAi to silence the pathogenic SOD1
mutant gene in ALS mice has been reported by three independent
groups. In mice expressing a mutated form of SOD1 (SOD1G93A),
increase in the survival and function of motor neurons and a marked
reduction in the muscular atrophy was observed after intraspinal
injection of SOD1-shRNA expressing lentiviral vector [44]. Similarly,
an EIAV-based lentiviral vector [45] and an AAV2 vector [46], both
expressing a shRNA against SOD1 mutant, when injected into the
muscle of mouse models of ALS, have producing similar therapeutic
effects. These results show that intramuscle or intraspinal delivery of
a viral vector silencing SOD1G93A provided a considerable thera-
peutic beneﬁt in ALS mouse models by delaying beginning of motor
neuron impairment and prolonging neuron survival. Nonetheless, a
major hurdle of viral vector-mediated RNAi therapy for humans is
the invasive delivery of viral vectors in the target neuronal
population which would require surgical intervention. Recently
AAV6 vectors expressing shRNA targeting SOD1 was deliveredintravenously (i.v.) in SOD1G93A mice, inducing a signiﬁcant
reduction in SOD1 protein in the muscles but without altering the
time course of the disease. This demonstrated the limited efﬁcacy of
viral vector-mediated RNAi for treating neurodegenerative disorders
if the viral vectors are delivered i.v. [47]. Similarly, several studies
reported efﬁcacy of RNAi in treating animal models of polyglutamine
disorders, such as Huntington's disease and SCA1. These disorders
are induced by expanded CAG repeat mutations in the genes for the
huntingtin or ataxin-1 proteins, resulting in abnormal polyglutamine
stretches which confer a disabling neurotoxic gain-of-function in HD
or SCA1, respectively. Recombinant AAV-shRNA vectors were
reported to efﬁciently silence the mutant huntingtin in the striata
or cerebellar lobules of murine models of HD and the successful
protein suppression was associated with a signiﬁcant reduction in
the HD neuropathology [48-50]. AAV vectors have also been used to
express siRNAs targeting a speciﬁc isoform of acid-sensing ion
channel (ASIC) in a mouse model of HD. The RNAi-mediated ASIC
silencing resulted in a decreased aggregation of the mutated
huntingtin in the striatum of HD mice [51]. Thus, these studies
provide evidence of the potential efﬁcacy of viral vector-mediated
RNAi for post-symptomatic HD therapy. Similarly, recombinant AAV
vectors, expressing human ataxin-1-targeting shRNA from the H1
promoter, have been injected at multiple sites in the midline
cerebellar lobules of SCA1 mice, expressing the human ataxin-1
disease allele in cerebellar Purkinje cells [52]. Using this approach,
successful target gene suppression was achieved, together with a
signiﬁcant improvement in motor performance even if only a small
percentage of all the cerebellar Purkinje cells were transduced with
the shRNA-expressing AAV. Alzheimer's disease (AD) is a progres-
sive neurodegenerative disorder affecting the elderly and character-
ized by the accumulation of amyloid-β protein (Aβ) in the CNS. A
great deal of effort has been made recently to develop treatments
reducing the accumulation of amyloid-β in the brain of AD patients
that leads to neuronal dysfunction and eventually to neuronal death.
Several independent groups have reported the efﬁcacy of viral
vector-mediated RNAi to directly reduce expression of amyloid
precursor protein (APP) or silence genes involved in APP processing.
Hong and colleagues developed HSV vectors inhibiting the accumu-
lation of Aβ by expressing APP-targeting shRNA. These workers
initially over-expressed the APP protein through injection of LV-APP
vectors in hippocampus and then observed a signiﬁcant inhibition of
Aβ deposits in the mouse brain after treatment with the HSV-APP/
shRNA vectors but not with the control vector [53]. However since
the functional role of APP in normal adult brain is not clear, silencing
APP function could represent a uncertain therapeutic strategy as it
could lead to physiological alterations in the treated brain. Abnormal
activity of the β-secretase enzyme BACE1 has been associated with
the accumulation of Aβ and with the neurodegenerative process in
the brain of AD patients. Injection of lentiviral vector expressing a
siRNA against BACE1 reduced both APP cleavage and the neurode-
generative process in the brain of APP transgenic mice [54]. Using
this approach the BACE1 activity was reduced but not completely
abolished. Similarly, lentiviral-mediated RNAi has been employed to
investigate the effect of angiotensin II (AT2) receptors silencing in
hippocampus of a mouse model of Alzheimer disease. AT2 silencing
was associated with a decreased Tau phosphorylation and Aβ
aggregation, demonstrating the important role of Aβ-induced AT2
oligomers as a previously unrecognised sign of ongoing neurode-
generation in AD [55]. Parkinson's disease (PD) is one of the most
common neurological disorders, caused by the death of dopaminer-
gic neurons in the substantia nigra (SN) that provide dopamine
input to the striatum. Since the localized area of intervention and the
discrete number of neurons that have to be targeted, RNAi could
represent a valid therapeutic approach for this disorder [56]. Overall
results conﬁrm the ability of siRNA-expressing viral vectors to
mediate sustained and prolonged suppression of target gene in
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neurodegenerative disorders. However, the potential beneﬁt of RNAi
as therapeutic strategy for human patients of neurological diseases
could be limited by safety factors. Recently, Grimm and colleagues
[57] reported fatal side effects in mice induced by AAV-mediated
shRNAs expression after low-pressure i.v. vector injection. Lethal
effects were observed only with certain shRNA constructs and were
not related to the target gene of the shRNA itself. In the past RNA
interference was shown to induce immune response and off-target
effects under certain conditions but the proper design of the siRNA
or shRNA sequences can avoid or limit these side outcomes.
However, the fatal effects reported by Grimm and colleagues seem
to be probably induced by a competition with the endogenous
microRNA pathway for post-transcriptional gene regulation [58].
Similarly, McBride and colleagues [59] reported severe neurotoxic
effects in mouse striatum induced by certain shRNA constructs, not
related to the silencing efﬁcacy or to the target gene of the shRNA
itself. This shRNA neurotoxicity, presumably induced by the high
levels of antisense RNA generated in mouse brain only by certain
shRNA constructs was mitigated when the same sequences were
placed into artiﬁcial miRNA expression systems. Moreover, the
difﬁculties of delivery of the siRNA-expressing vectors to the brain
and the safety concerns associated with the use of viral vectors could
limit the application of RNAi-based therapy in humans. Nonetheless,
RNAi still remains a promising therapeutic approach for the
treatment of neurodegenerative disorders and recent progress in
non-viral siRNA delivery could represent a solution in overcoming
the blood-brain-barrier and successfully delivering the siRNA into
the brain.
2.5. Transgenic RNAi
In addition RNAi has been successfully employed for the generation
of prolonged, stable, loss-of-function phenotypes through shRNA-
mediated transgenic RNAi. shRNA expressing vectors have been
transfected into mouse ES cells using electroporation to generate
stable integrants with target gene knockdown that could be then
injected into blastocysts. Furthermore, stable passage of the shRNA-
expressing vector from the ES cells to adult mice and germline
transmission to the F1 progeny has been demonstrated [60]. Since
lentiviral vectors can infect mouse ES cells and are believed to be
resistant to proviral silencing during development, they have been
used for transducing ES cells with the shRNA-expressing constructs
[61,62]. To overcome the limitations of the constitutive and wide-
spread gene knockdown of transgenic RNAi animals, the Cre–loxP
recombination system has been employed to control the spatial–
temporal expression of shRNAs. In this system, the shRNA-expressing
vector is modiﬁed in order to incorporate a speciﬁc sequence that
prevents transcription from the vector, ﬂanked by loxP sites. Since
these sites are recognized by the Cre recombinase, the original open
reading frame of the vector is restored only by a Cre-mediated
recombination event. Using inducible Cre expression systems, such as
those controlled by tetracycline or tamoxifen, along with transgenic
RNAi, it could be possible to investigate the phenotypical outcome for
brain-speciﬁc genes loss of functionwith temporal and spatial-speciﬁc
control. This approach possesses several advantages over gene
knockout approach by homologous recombination since it is faster,
cheaper and is applicable to severalmammalian species [63]. Zhou and
colleagues [64] employed transgenic RNAi to investigate the effect of
silencing a Parkinson disease-associated gene, the PTEN-induced
putative kinase 1 (PINK1) in the mouse brain. They developed RNAi
transgenicmicewith inducible expression of a PINK1-targeting shRNA
using the Cre-loxP inducible U6 promoter. The expression of PINK1
was effectively silenced by more than 95% in mouse brain after shRNA
induction but this did not result in loss of dopaminergic neurons,
suggesting that loss of PINK1 gene expression in mice is not sufﬁcientto induce Parkinson's disease phenotypes. The results showed also the
validity of the Cre-loxP regulated U6 promoter for conditional gene
silencing in vivo, since shRNA expressionwaswidespread in all tissues
of the transgenic mice only after Cre induction.
3. Viral vectors
Viral vectors are commonly used in a wide number of applications,
such as gene therapy to restore normal function or for gene expression
modulation to investigate the function of a target gene or to conﬁrm its
involvement in a disease mechanism [65]. They offer the advantage of
manipulating gene expression in a wide range of mitotic and post-
mitotic cells and to mediate persistent expression of the delivered
genetic sequences (Table 1). Among the different viral types, retro-
viruses are RNA viruses which reverse-transcribe their RNA viral
genome into double-stranded DNA that is then stably inserted into the
host genome. They mediate high gene transfer efﬁciency, low
immunogenicity and mediate persistent expression of the transgene.
However, due to their ability to integrate into host DNA they could be
associated with risk of insertional mutagenesis. DNA viruses contain a
single- or double-stranded DNA genome. The most predominant
viruses used are the Adenovirus, AAV and HSV thanks to their broad
cell tropism and efﬁcient infection and gene transfer. Viral vectors
based on adenovirus possess the advantages of having large insert
capacity and relative ease of manipulation. On the other hand, their in
vivo use has been limited by vector-associated immunotoxicity,
inﬂammation, and transient transgene expression [66]. AAV-based
vectors are attractive for their low immunogenicity and the ability to
persist as stable episomal form in the infected cells, allowing lasting
transgene expression without risk of insertional mutagenesis. More-
over, their small size makes them ideal for application requiring
diffusion into wide brain area. A disadvantage is their limited insert
capacity, which can be an obstacle if it is required the expression of
large transgenic insert. HSV is of interest because of its large insertional
capacity for foreign DNA, its natural tropism toward neurons, its
relative stability and long-term expression of transgenes, particularly
in neurons. However HSV vectors have been associated with toxicity
after viral infection. More recently, numerous new viral vectors have
been developed based on vaccinia virus, human cytomegalovirus,
Epstein–Barr virus and others but their used in vivo is still limited [65].
3.1. Viral vector applications for neurological disorders
In recent years, viral vectors have been extensively used for the
generation of mouse models of interest in the study of neurological
disorders. As previously described, viral vectors have been effectively
employed tomediate persistent RNAi in the brain for the generation of
animalmodelswith selective target gene silencing or to validate RNAi-
based therapeutic approaches in mouse model of gain-of-function
neurodegenerative disorders. In addition, they have been employed
for the study and for the treatment of those disorders characterized by
a loss-of-functionmechanism and for the generation of mousemodels
for gain-of-function disorders, through persistent delivery of the
therapeutic gene. They can be employed for either inducing persistent
genetic manipulation in the whole body through transduction of the
mouse germ line or in speciﬁc area of the central nervous system
through intracerebral injection. Several routes for viral vectors
delivery in the brain are available: intracerebral stereotaxic injection,
intrathecal and intraventricular injection and intravascular infusion
with or without modiﬁcation of the blood-brain-barrier. The choice of
route for viral vectors administration needs to be carefully considered
since it affects neuronal cells transduction efﬁciency and spatial
distribution, aswell as the level of transgene expression in the infected
cells [67]. Intracerebral injection offers the advantages of low toxicity,
high local vector concentrations and localized transgene delivery but it
does not allow wide viral vector distribution and requires invasive
802 C. Cazzin, C.J.A. Ring / Biochimica et Biophysica Acta 1802 (2010) 796–807surgical intervention. Ubiquitous distribution of viral vectors in the
CNS could be achieved by intrathecal or intraventricular injection but
thesemethods do not permit spatial selectivity of delivery and require
a large amount of vectors. Finally, intravascular viral vector applica-
tions do not require invasive surgical intervention but necessitate the
use of high vector concentrations due to losses in peripheral organs
such as the liver.
Viral vectors represent a valid alternative for the generation of
mouse models characterized by target gene over-expression over the
classical transgene knock-in models. They allow transgene expression
in a precise spatial–temporal manner in the desired animal strain and
in a less time consuming manner. Viral vectors have been used to
over-express alpha-synuclein (α-Syn), a Parkinson's disease-related
protein, in the substantia nigra pars compacta of mice to generate an
innovative PD mouse model. Viral vector-mediated α-Syn over-
expression resulted in a rapid degeneration of nigrostriatal neurons,
which was not previously observed by genetic mutations in mice [68].
Lentiviral-mediated over-expression of a mutated APP form in mouse
hippocampus resulted in rapid Aβ accumulation andwas employed to
quickly investigate the therapeutic potential of Aβ protein suppres-
sion by RNAi in the brain as novel treatment for AD [53]. However, the
major drawbacks of viral-mediated gene transfer comparedwith gene
knock-in in transgenic mice are the labor-intensive nature of the
stereotactic injections, and the difﬁculty in obtaining widespread and
controlled level of transgene expression. Viral vector-mediated over-
expression can be employed also to investigate the effect of target
gene expression on the behaviors or in a speciﬁc molecular pathway
of knock-out mice. As example, an HSV1-based vector was used to
analyze the effect of restoring the expression of Kv1.1 protein in the
hippocampus of Kv1.1 knock-out mice [69]. The functional role of α-
synuclein in the dopamine synthesis was investigated though LV-α-
Syn injection in dopaminergic neurons of α-Syn knockout mouse
(ASKO) olfactory bulb. The LV-mediated over-expression of wild type
α-Syn in the ASKOmice revealed the important role of this protein on
TH regulation, dopamine synthesis, and cell viability [70].
Gene therapy holds great promise for the treatment of human
disorders and the numerous applications of viral vectors in the last
years have involved the validation of potential therapeutic
approaches reversing the loss-of-function phenotype associated
with numerous neurological diseases [71]. Several studies have been
carried out in mouse models of neurological disorders to explore the
efﬁcacy of over-expressing potential therapeutic genes, in particular
for the treatment of neurodegenerative disorders such as HD, PD and
ALS. Many articles have been published in recent years describing
viral vector-mediated over-expression of various neurotrophic factors
such as glial cell line-derived neurotrophic factor (GDNF) and brain-
derived neurotrophic factor (BDNF) for the potential treatment of
Huntington's and Parkinson's disease. AAV2-mediated GDNF over-
expression in striatum of a pre-symptomatic mouse model of HD
ameliorated behavioral deﬁcits on the accelerating rotorod and hind
limb clasping tests and decreased the number of neurons containing
mutant huntingtin-stained inclusion bodies, a characteristic of HD
pathology [72]. Similarly, AAV-mediated over-expression of BDNF and
GDNF has been shown to ameliorate the symptoms of an acute mouse
model of HD [73]. These results open the possibility of using viral
vector-mediated delivery of neurotrophic factors as viable treatment
for patients suffering fromHD. The neuroprotective effect of GDNF in a
murine model of Parkinson's disease has also been demonstrated. In
this study a lentiviral vector was used to over-express GDNF in the
substancia nigra of a 6-hydroxydopamine (6-OHDA) model of
Parkinson’s disease [74]. The same group employed lentiviral vector
to over-express the antioxidant enzyme glutathione peroxidase
(GPX) in nigral dopaminergic neurons prior to intrastriatal injection
of the toxin 6-OHDA in mice. The authors reported a small but
signiﬁcant neuroprotection effect of GPX in these cells against drug-
induced toxicity [75]. An alternative approach to delivering neuro-trophic factors in the brain affected by neurodegenerative disorders is
to directly activate the intracellular signaling pathways responsible
for their effects. Ries and colleagues [76] used an AAV1 vector to over-
express the myristoylated, constitutively active form of the oncopro-
tein Akt/PKB in the substantia nigra of a murine model of Parkinson's
disease. The Akt/PKB over-expression caused a pronounced neuro-
trophic and neuroprotective effect in the dopaminergic neurons of
affected mice. The potential therapeutic effect of insulin-like growth
factor 1 (IGF1) in retarding the progression of the fatal neurodegen-
erative disease ALS was investigated in symptomatic ALS mice. The
injection of AAV-IGF1 vectors in the deep cerebellar nuclei reduced
ALS neuropathology and signiﬁcantly extended life span in ALS mice
[77]. Interestingly, systemic delivery of AAV-IGF1 vectors was also
shown to improve motor function in a mouse model of diabetic
peripheral neuropathy [78]. Viral vectors have also been successfully
applied to develop novel treatments for muscular dystrophies (MDs)
that are a heterogeneous group of inherited disorders characterized
by progressive skeletal muscle degeneration. Several gene replace-
ment and repair strategies mediated by viral vectors have been
developed inmousemodels of MDs, demonstrating the efﬁcacy of this
therapeutic strategy for the treatment of this class of disorders [79].
As an example, the therapeutic potential of alpha-sarcoglycan gene
(alpha-SG) replacement for patients suffering of limb-girdle muscu-
lar dystrophy type 2D (LGMD 2D) was investigated through AAV8-
mediated alpha-SG expression in alpha-SG-deﬁcient mice. A single
intramuscular injection in the knock-out mice resulted in a reversal
of the muscle pathology and improvement in the contractile force
[80].
Viral vector-mediated enzymatic complementation represents a
promising treatment for those rare inherited neurodegenerative
disorders characterized by the lack of single speciﬁc enzymes that
lead to premature death. The efﬁcacy of these novel genetic
therapeutic approaches using viral vectors has been investigated in
mouse models of the rare neurological inherited disorders Mucopo-
lysaccharidosis (MPS) IIIB disease, Tay–Sachs (TS) disease, Niemann–
Pick type A disease (NPA) and others. MPS IIIB is a lysosomal storage
disease, caused by the deﬁciency of α-N-acetylglucosaminidase
(NaGlu) enzyme that leads to severe progressive neurological deﬁcits
and to premature death. Intravenous and intracisternal injection of
AAV vector over-expressing the NaGlu enzyme in young adult mice
affected by MPS IIIB was shown to signiﬁcantly prolong the lifespan
and improve behavioral performances [81]. Tay–Sachs-related dis-
eases are characterized by lysosomal storage of GM2 ganglioside
caused by deﬁciency of α-hexosaminidase A, a heterodimeric protein.
Intracranial inoculation of recombinant AAV vectors encoding the
human β-hexosaminidase subunit genes has been shown to increase
the survival and improve the behavioral performance in a mouse
model of Tay–Sachs disease [82]. Similarly, HSV-mediated expression
of the hexosaminidase A alpha-subunit in the cerebellum and spinal
cord of a TS animal model, through injection in the internal capsule,
restored the enzyme activity and abolished the GM2 ganglioside
storage, without signs of viral vector toxicity [83]. AAV vectors were
also used to express the therapeutic gene acid sphingomyelinase
(ASM), which activity is lacking in the human Niemann–Pick type A
disease, in the deep cerebellar nuclei of ASM knock-outmice, resulting
in the reduction of storage pathology and correction of the behavioral
deﬁcits [84]. Taken all together, these studies indicate that viral
vector-mediated expression of therapeutic genes has realistic poten-
tial for treating these rare human neurological genetic diseases that
currently lack effective treatment.
Viral vectors have been of huge value to investigate potential
therapeutic approaches for the treatment of brain tumors [85]. The
effect of different tumor suppressor genes in inhibiting growth of
tumor xenografts in nude mice has been investigated by using both
retrovirus- and adenovirus-mediated gene transfer. Adenovirus has
been used to express the tumor suppressor gene phosphatase and
Table 2
Transgenic mouse models of human neurological diseases generated with YACs, BACs
or PACs.
Human transgene Vector Human neurological
disease
Reference
Huntingtin with 46, 72 and 120 CAG
repeats
YAC Huntington disease [99-101]
Huntingtin with 97 CAG repeats BAC Huntington disease [102]
Ataxin 8 with [(CTA)3(CTG)5CCG
(CTG)7(CCG)(CTG)104] conﬁguration
BAC Spinocerebellar
ataxia type 8 (SCA8)
[103]
Ataxin 3 with 15 and 84 CAG repeats YAC Spinocerebellar
ataxia type 3 (SCA3)
[104]
APP YAC Alzheimer disease [105]
Presenilin-1 YAC Alzheimer disease [113]
Tau PAC Alzheimer disease [114]
Parkin-Q311X BAC Parkinson disease [106]
Chromosome 21 region 21q22.2 YAC Down's syndrome [107]
DYRK1A BAC Down's syndrome [108]
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bearing mutations in this gene. PTEN expression resulted in the
blockade of both tumor invasiveness and angiogenesis [86]. Both
retroviral and adenoviral vectors have been employed to mediate the
expression of growth arrest speciﬁc-1 (GAS1) gene in astrocytoma
xenografts in nude mice and both showed efﬁcacy in inhibiting tumor
growth [87,88]. Similarly, the effect of anti-angiogenic genes on tumor
growth has been investigated bymeans of viral vector-mediated over-
expression. As an example, AAV8-mediated expression of an inhibitor
of vascular endothelial growth factor (VEGF) reduced the tumor
volume and increased the survival after injection in different mouse
models of glioblastoma multiforme [89]. Recently, the potential of
oncolytic replication-selective HSV as a new platform for brain cancer
therapy has been evaluated in nude mice bearing xenografts. These
HSV-based vectors are characterized by mutations that bestow upon
the virus the ability to selectively replicate in and lyse the dividing
tumor cells. For example, the oncolytic HSV vector G47Δ efﬁciently
induced regression of different forms of schwannoma tumor
implanted subcutaneously in nude mice [90]. The efﬁcacy and the
safety of several oncolytic HSV vectors in human brain tumors have
been already studied in several clinical trials but more efforts are
needed to increase the therapeutic beneﬁt of the treatment. Liu and
colleagues [91] investigated the potential of expressing onco-
suppressor genes by oncolytic HSV to increase the therapeutic
efﬁcacy. The dominant-negative ﬁbroblast growth factor (FGF)
receptor (dnFGFR) has been expressed using an oncolytic HSV in
glioma xenografts and has demonstrated increased efﬁcacy in
inhibiting tumor growth and angiogenesis compared to the standard
oncolytic HSV. Several gene therapy clinical trials are currently
ongoing using viral vectors for the treatment of nervous system
tumors and the possibility to combine viral vector-mediated gene
therapy with classical treatments such as surgical and chemothera-
peutic or radiation treatments could signiﬁcantly improve survival
and the quality of life of human patients with brain tumors.
3.2. Viral vector applications for transgenic mice
Viral vectors can be used for the generation of more sophisticated
conditional transgenic mice, using the Cre-loxP recombination
strategy [92]. Exploring the functional role of a putative target gene
is routinely carried out by means of transgenic mouse models, in
which the target gene is either knock-down or knock-in. Brain-
speciﬁc gene manipulation or modulation of the adult animal is likely
to be required if the target gene is of neurological interest or if it is
involved in the early developmental stages. Moreover, since the same
gene may have different effects in different brain regions, the effect of
the gene in a speciﬁc brain area may need to be shielded from effects
in other areas. Several strategies have been developed over the past
years to create conditional mouse models with speciﬁc temporal and
spatial patterns of transgene expression such as combination of the
Cre-loxP system with tissue-speciﬁc or inducible promoters. Howev-
er, these strategies do not allow transgene manipulation in a speciﬁc
localized brain area. Infection of somatic tissues of loxP transgenic
mice with a viral vector expressing Cre recombinase is a means of
allowing ﬂexible temporal–spatial control [93]. Since chronic antide-
pressant treatment was reported to increase BDNF expression in
dentate gyrus (DG) but not in CA1 region of hippocampus, Adachi and
colleagues [94] employed AAV-mediated Cre expression to investi-
gate the role of BDNF in subregions of the hippocampus on the
etiology of depression and anxiety. They developed ﬂoxed mice in
which BDNF was only deleted in the presence of Cre recombinase and
delivered AAV-Cre virus speciﬁcally in dentate gyrus or CA1 regions of
these transgenic mice. With this approach, they reported that
selective loss of BDNF in either DG or CA1 did not induce
depression-like behavior but that selective loss of BDNF in the DG
but not the CA1 region reduced the response to antidepressant drugs.Similarly, the effect of NMDA receptors on seizure proﬁle in
hippocampal CA3 region was investigated by viral vector expression
of Cre recombinase in loxP-GluRγ1 mice, obtained by inserting the
loxP sites in the GluRγ1 gene [95]. The inducible ablation of NMDA
receptors in the hippocampal CA3 region of adult brain induced EEG
spikes with larger amplitude compared to control and allowed to
investigate the role of hippocampal CA3 NMDA receptors in
controlling the excitability of the neural recurrent network oscillation.
Moreover, viral vector-mediated Cre expression was employed to
develop a mouse model of Friedreich's ataxia (FA), the most common
of the hereditary ataxias characterized by mutations in the frataxin
gene (frda). HSV1-Cre viruses were injected in the brainstem of loxP-
frda mice to generate localized suppression of frataxin protein. These
conditional knock-out mice developed a motor coordination deﬁcit
that was recovered after injection with HSV-1 vectors expressing
human frataxin gene [96].
4. YAC, BAC, PAC and other vectors
Transgenic animals expressing the gene of interest are commonly
applied to the study of neurological disorders and a large effort has
been made in recent last years to generate animal models resembling
the pathological or physiological state in vivo as closely as possible [5].
One of the main problems encountered during the creation of
transgenic mice is to control the expression of the transgene in
order to mimic the in vivo state. In case of stochastic integration of the
transgenic construct, the surrounding sequences in the host genome
can modify the transgene expression pattern. In addition, most of the
mammalian genes possess several regulatory sequences determining
the ﬁnal level of gene expression. The chromosomal position effect
due by stochastic transgene integration can be overcome by targeting
the site of integration by homologous recombination in ES cells.
Moreover by adding all the regulatory sequences in the transgenic
construct it is possible to obtain optimal transgene expression
regardless of its position of integration. Since classical transgenic
technologies are unable to introduce standard preparations of
genomic fragments N40–50 kb, the ability to deliver vectors of large
cloning capacity is required. These characteristics are present in
artiﬁcial-chromosome type vectors such as yeast artiﬁcial chromo-
somes or YACs, bacterial artiﬁcial chromosomes or BACs and P1-
derived artiﬁcial chromosomes or PACs [97]. Thanks to their
properties, these vectors have been extensively used over the past
years to generate transgenic animals of use in the ﬁeld of neurological
disorders (Table 2). YACs are yeast artiﬁcial chromosomes with a DNA
capacity of N2 Mb that are stably propagated in yeast as artiﬁcial
chromosomes. Thanks to their large cloning capacity and the high
versatility to genetic manipulation by homologous recombination in
yeast, they are very attractive for gene transfer experiments. Themain
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possibility to ensure an optimal level of transgene expression, without
positioning effect through providing all the regulatory elements of the
transgene. Because of their large size, however, such cloning vectors
are associated with several disadvantages such as the difﬁculty in
handling, the insert instability and the complex process for advisable
isolation of YAC from yeast chromosome. The bacterial artiﬁcial
chromosomes are circular plasmid DNA molecules hosted in Escheri-
chia coli which can accommodate up to 300 kb of foreign DNA while
PACs are derived from the E. coli bacteriophage P1. Compared to YACs,
BACs and PACs can be manipulated more easily but rearrangements
and transgene fragmentations are still possible [98].
4.1. YACs, BACs and PACs for neurological transgenic mice
Because of the potential to express transgenes in an appropriate
spatial- and temporal-speciﬁc manner, large vectors such as YACs,
BACs and PACs have been extensively used to generate transgenic
mice with the aim of generating improved animal models of human
neurological disorders. In particular, both YACs and BACs have been
extensively used to generate enhanced animal models of neurode-
generative disorders such as Huntington, Parkinson, SCA, Alzheimer
and others (Table 2). Several independent groups applied YAC and
BAC vectors to generate suitable mice models for examining the
mechanism of neurodegeneration occurring in Huntington disease.
As previously stated, human HD is caused by a trinucleotide CAG
repeat expansion in the gene coding for htt translated into a
polyglutamine stretch in the protein and the size of CAG expansion
in the gene is directly proportional to the severity of the disease.
YACs were used to express the human mutated form of huntingtin
(htt). All the regulatory endogenous regions were included in the
vectors together with the genomic sequence coding the mutated htt
containing different numbers of copies of the CAG repeats. As in
human disease, the severity of the disease increases with the size of
CAG expansion in the YAC vector and in particular YAC128 mice
(with 128 polyglutamine repeats) present motor and cognitive
deﬁcits comparable with the human disease [99]. These animal
models have been widely investigated to explore the mechanism
underlying the selective neurodegenerative process that resembles
the process occurring in human HD patients [100]. For example,
increased calpain activity in striatal medium-sized spiny neurons
(MSNs) was observed in YAC128 mice, suggesting that calpain could
be involved in the NMDA-induced apoptosis occurring in MSNs of
Huntington patients [101]. Similarly, BAC-mediated transgenic
mouse models of Huntington disorder have been developed that
express the human mutant form of huntingtin with 97 glutamine
repeats under the control of the endogenous regulatory machinery
[102]. YACs and BACs have been utilized to create transgenic mice
models of spinocerebellar ataxia by using them to express the
mutated form of the ataxin protein under control of its endogenous
promoter and regulatory sequences [103,104]. These transgenic
mice therefore represent an optimal model to investigate the
degenerative process and possible therapeutic approaches. Superior
genetic models of Alzheimer's disease have been created using the
YAC approach. Entire genomic copies of the human mutated APP or
the mutated presenilin-1 (PS-1) genes, together with their regula-
tory elements have been introduced into transgenic mice. These
animals were shown to develop many unique feature characteristics
of human AD that were not observed in other transgenic mouse
models of AD [105]. Similarly, BAC transgenic mouse model of
Parkinson disease was created by expressing a C-terminal truncated
human mutant parkin (Parkin-Q311X) in dopaminergic (DA)
neurons under a dopamine transporter promoter [106]. This
mouse model showed progressive hypokinetic motor deﬁcits and
degeneration of DA neurons in substantia nigra, demonstrating the
toxic gain of function of parkin mutants. The possibility to clonelarge fragment of genomic DNA has been extremely useful in cases
in which the sequence of a particular gene is not known or when is
necessary to investigate the effect of multiple genes as in the case of
aneuploidy syndromes such as Down syndrome (DS). Several
transgenic mice with YACs expressing part of the sequence of
human chromosome 21 (HSA21) have been generated and their
behavioral proﬁle analyzed [107]. BAC containing the human
DYRK1A gene located on human chromosome 21q22.2 was used
to create a transgenic mouse model for the study of DS mental
retardation. The transgenic mice exhibited signiﬁcant impairment in
spatial learning and memory tasks and alteration in hippocampal
synaptic plasticity [108].
Taken together these studies demonstrate the validity of using
YACs, BACs and other large cloning vectors to develop transgenic mice
with a high level of transgene expression control, that represent
invaluable animal models for the study of the pathogenesis and of the
possible therapeutic strategies for neurological disorders.
5. Mice versus other mammals
Using mice to create suitable animal models for the study of
speciﬁc disorders or to investigate the role of candidate genes has
obvious advantages. First of all manipulation of the mouse genome
to create speciﬁc genetic changes by microinjection of DNA into
fertilized eggs or by homologous recombination in embryonic stem
cells is relatively easy compared to other mammalian species such
as rats. Another advantage is the availability of “inbred strains” of
mice that are genetically identical, obtained by breeding sibling mice
over 20 generations. Since these animals present the same genetic
background, they can be compared for the response to a treatment
or a genetic modiﬁcation between different laboratories [109].
However the choice of the genetic background in creating the
animal model is a critical point that requires extensive consideration
since different genetic traits could contribute in several ways to the
mutant phenotype [110]. As described in this review, innovative
technologies for gene expression manipulation, such as RNAi and/or
viral vectors and DNA vectors such as YACs and BACs have been
extensively applied in mice in order to create sophisticated animal
models of great value in the study of human neurological disorders.
Indeed, the human genome shares to a great extent the same genes
as that of the mouse. Therefore, by engineering a genetic defect that
causes a human neurological disease, into the mouse genome, is
likely to result in the same disease in mice. Undeniably, numerous
mice models of neurological disease that have been produced over
recent years have developed many of the same symptoms and
behavioral traits of human patients of neurological disorders [111].
In this context, RNAi and viral vectors have been applied to create
even more sophisticated genetic manipulation in mice. It has been
possible to analyze the effect of transgene expression modulation in
speciﬁc spatial- and temporal-manner and to investigate the
potential of therapeutic approaches in pre-established mouse
models of neurological disorders. For these reasons, mice represent
one of the most exploited laboratory animal species in the ﬁeld of
neurological disease research. However, it has to be considered that
genetic manipulation in mice could be associated with several
disadvantages that could make it difﬁcult to elucidate the phenotype
associated with a speciﬁc genetic change [112]. As previously seen,
one of these drawbacks is the variations of the behavioral phenotype
deriving by the same genetic manipulation in different strain of
mice. Moreover, the presence of a rich diversity of inbred mouse
strains could complicate the analysis of the effects of target gene
mutation. In addition, recent experimental evidences suggest that
epigenetic changes can derive from the transmission of RNA or
protein in the oocyte or sperm from transgenic parents to non-
transgenic offspring [112]. The presence of this phenomenon limits
the use of non-transgenic littermates as controls only after careful
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and psychological point of view, rats have been the organism of
choice for decades and the ﬁrst ever laboratory animal models used
since their physiological processes are similar to humans and
because their larger dimension compared to mice make them
more suited to the application of invasive techniques such as
cannula implantation, and carrying out physiological tests. In this
context, the recent tools for genetic manipulation, RNA interference
and viral-vector transgene delivery, present the obvious advantage
of being applicable not only to mice but also rats and other species.
6. Conclusions and perspective
Extensive research has been carried out in recent years to develop
and apply innovative technologies for targeted gene manipulation.
Since the ﬁrst application of homologous recombination and DNA
microinjection in mice, many attempts have been made to create
more sophisticated models resembling the human pathological state
or for further investigating the functional role of target genes.
Transgenic mouse models have contributed largely to the under-
standing of the genetics of neurological disorders and to the
development of therapeutic strategies. However, more robust and
rapid methods for precise and specialized assessment of phenotype
are required. Undoubtedly RNA interference has represented an
innovative method for analysis of gene function through selective
gene silencing and has been applied extensively to the study of
neurological disorders. Besides its physiological role in controlling
gene expression through miRNAs, it has provided an efﬁcient tool for
functional genomics and target validation processes. Using osmotic
mini-pumps or in association with viral vectors, it has allowed us to
investigate the role played by several genes in neurological disorders.
At the same time, considerable effort has been made recently to
investigate the therapeutic potential of RNAi in human neurological
disorders. Novel therapeutic approaches have been opened up for this
wide class of disorders since RNAi has demonstrated therapeutic
efﬁcacy in several mouse models of human neurological states and
clinical trials are already ongoing for other classes of disease. Several
challenges face translation of RNAi to clinic, however, namely delivery
and safety. Studies in mouse models will help in clarifying the
effective potential of RNAi as a therapeutic strategy and to investigate
possible side effects.
Viral vectors represent another method of manipulating gene
expression in adult mice and have been applied both in target gene
validation and in the investigation of potential therapeutic strategies.
Viral vector-based approaches differ from the standard transgenic
method since they can mediate target gene manipulation in well-
deﬁned regions of the adult CNS and they have been successfully used
to generate advanced mice models of neurological disorders through
over-expression of the disease-causing protein in speciﬁc brain
regions or neuron populations. More signiﬁcantly, several reports
have recently been published describing efﬁcacy of viral vector-
mediated transgene expression in the treatment of neurological
disorders in several mouse models. However the efﬁcacy of viral
vector-mediated gene manipulation to treat human neurological
disorders needs intensive investigation due to the safety concerns
associated even if it could represent a successful approach for
progressive neurodegenerative conditions disorders that currently
lack any effective treatments. Finally, large DNA vectors such as YACs,
BACs and PACs represent an innovative means of creating animal
disease models that resemble the in vivo pathological state more
closely, invaluable for investigating the efﬁcacy and safety of novel
therapeutic treatments.
In conclusion, the advent of innovative methods for genetic
manipulation has allowed the generation of superior mouse models
that represent a considerable resource to investigate the pathogenesis
and the therapeutic approaches in neurological disorders.References
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